Xtx Topco LTD Macrogenics Inc Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Macrogenics Inc stock. As of the latest transaction made, Xtx Topco LTD holds 11,178 shares of MGNX stock, worth $35,881. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,178

Holding current value

$35,881

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $33,534 - $62,037	11,178 New	11,178 $36,000
Q1 2024 May 13, 2024	BUY	$9.77 - $21.47 $280,838 - $617,155	28,745 New	28,745 $423,000
Q3 2023 Nov 13, 2023	BUY	$4.48 - $6.19 $8,628 - $11,921	1,926 Added 3.75%	53,269 $248,000
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $22,716 - $37,074	-4,917 Reduced 8.74%	51,343 $274,000
Q1 2023 May 12, 2023	BUY	$4.82 - $7.24 $40,970 - $61,540	8,500 Added 17.8%	56,260 $403,000
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $106,045 - $221,615	-31,750 Reduced 39.93%	47,760 $320,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $94,956 - $164,675	-31,547 Reduced 28.41%	79,510 $275,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $249,878 - $1.11 Million	111,057 New	111,057 $328,000

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

Bellevue Group Ag Kuesnacht, V8

9.93M
Shares

$31.9 Million
0.55% of portfolio
Armistice Capital, LLC New York, NY

6.26M
Shares

$20.1 Million
0.34% of portfolio
Black Rock Inc. New York, NY

5.4M
Shares

$17.3 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.36M
Shares

$14 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.54M
Shares

$11.4 Million
0.01% of portfolio

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $197M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account